Taxonomy

Repurposing Drugs for CMT1A: An Encouraging Approach

Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common form

DNA-Based Therapeutics: A Promising Future for CMT2E Treatment

Researchers at the University of Miami, supported by the Charcot-Marie-Tooth

CMT-SORD: Share Your Story

CMT-SORD: What is Your Story? For many with CMT, the

Chris Oviatt – Golfer with CMT

Chris Oviatt is a golfer from Oregon who was diagnosed

CMTA Announces New Center of Excellence in Thailand

The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of

CMTA Appoints David Skarinsky to its Therapy Expert Board

The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth

NMD Pharma Receives FDA Approval to Initiate Phase II Clinical Trial of NMD670 in CMT Patients

The Charcot-Marie-Tooth Association (CMTA) is excited to share that our

CMTA’s $240K Investment Targets Gene Replacement Therapy in CMT4 Subtypes

The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth

From Gene Discovery to Gene Editing: Closing the Diagnostic Gap and Developing CRISPR/Cas9 Capabilities in CMT

Finding Your Gene Researchers have discovered over 120 genes linked

2024 CMTA Patient & Research Summit Registration is Now Open

The 2024 CMTA Patient & Research Summit will take place